RecruitingPhase 1Phase 2NCT06625671

A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE/CLE Participants

A Randomized, Double-Blind, Phase 1/2a Study to Evaluate the Safety, Tolerability, PK and PD of DB-2304 for Injection in Healthy Adult Participants and Participants With Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus

Sponsor

DualityBio Inc.

Enrollment

148 participants

Start Date

Oct 4, 2024

Study Type

INTERVENTIONAL

Conditions

Systemic Lupus Erythematosus (SLE) or Cutaneous Lupus Erythematosus

Summary

A Phase 1/2a Study of DB-2304 in Healthy Participants and Participants with Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called DB-2304, a drug called Placebo, and others for people with systemic lupus erythematosus (sle) or cutaneous lupus erythematosus. The study is currently recruiting participants at 7 locations. People eligible for this study include aged 18 Years to 70 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDB-2304

DB-2304

DRUGPlacebo

Placebo

DRUGPrednisone

Prednisone

Locations(7)

US06-0

La Palma, California, United States

US03-0

Clearwater, Florida, United States

US05-0

Orlando, Florida, United States

US08-0

Syracuse, New York, United States

US04-0

Irving, Texas, United States

US02-0

San Antonio, Texas, United States

Site AUS01-0

Melbourne, Victoria, Australia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06625671